Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: Are they equivalent?

Conclusion Although the two tiotropium formulations have similar efficacy, current data cannot prove safety equivalence, since respimat may be associated with increased cardiovascular and general mortality, especially in patients with comorbid diseases.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research